Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

Novo Nordisk

In a presentation at the American Heart Association's (AHA's) 2025 Scientific Sessions, researchers on Tuesday shared data from Novo Nordisk A/S' (NYSE:NVO) Coramitug Phase 2 trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Data

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.